Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Sevabertinib with Itraconazole or Carbamazepine in Healthy Participants
NCT06348888Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevabertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bayer. Primary endpoints: Area under the curve of BAY2927088 at Day 14 and Maximum observed concentration of BAY2927088 at Day 14. Started Apr 2024; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06348888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348888.